Tesamorelin vs CJC-1295: FDA-Approved vs Research Peptide for Fat Loss

Tesamorelin and CJC-1295 are both GHRH analogs—they mimic growth hormone-releasing hormone and stimulate the pituitary to secrete GH. But they occupy very different regulatory and clinical positions. Tesamorelin (brand name Egrifta) is FDA-approved with Phase 3 clinical trial data. CJC-1295 is an off-label research peptide with no approved clinical use. Understanding those differences—and why they matter—is essential before choosing between them.

What they are

Tesamorelin is a synthetic GHRH analog consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group attached to stabilize it against DPP-IV degradation. It was developed by Theratechnologies specifically to treat HIV-associated lipodystrophy (abnormal fat accumulation around the abdomen and organs) and received FDA approval for this indication in 2010. Subsequent studies showed visceral fat reduction in non-HIV populations as well, expanding interest in its off-label use.

CJC-1295 (in its no-DAC form, also called Mod GRF 1-29) is a modified GHRH 1-29 fragment with four amino acid substitutions for DPP-IV resistance. The DAC version adds an albumin-binding complex extending its half-life to days. Neither version is FDA-approved. CJC-1295 is used in research settings and off-label by anti-aging practitioners, athletes, and biohackers.

Mechanism: how similar are they?

Both bind to the GHRH receptor on pituitary somatotroph cells, stimulating GH synthesis and release. The key mechanistic differences:

| Feature | Tesamorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | |---|---|---|---| | GHRH sequence | Full 44-AA + hexenoic acid | Modified 1-29 fragment | Modified 1-29 fragment + DAC | | Half-life | ~26–38 minutes | ~30 min–2 hours | 6–8 days | | DPP-IV resistance | Yes | Yes | Yes | | GH release pattern | Pulsatile | Pulsatile | Continuous | | FDA approval | Yes (HIV lipodystrophy) | No | No | | Primary clinical use | Visceral fat reduction | GH secretagogue (off-label) | GH secretagogue (off-label) |

Tesamorelin uses the full GHRH sequence rather than the truncated 1-29 fragment, which may provide slightly more complete receptor activation—though the practical clinical difference between tesamorelin and Mod GRF 1-29 at equal GH-stimulating doses is unclear.

The visceral fat evidence

This is where tesamorelin stands clearly apart. The clinical evidence for tesamorelin specifically targeting visceral adipose tissue (VAT) is among the strongest for any peptide in existence.

Key trials:

• LIPO-010 (2010): 816 patients with HIV-associated lipodystrophy. Tesamorelin 2mg/day reduced VAT by ~15–18% vs. placebo at 26 weeks. This was the pivotal trial for FDA approval.
• Spooner et al. (2012): Continuation showing maintained VAT reduction at 52 weeks.
• Stanley et al. (2012): In non-HIV adults with abdominal obesity, tesamorelin reduced VAT by ~18% and reduced carotid intima-media thickness (a cardiovascular risk marker).
• Multiple subsequent studies: Consistently show tesamorelin reduces VAT, improves triglycerides, and may improve cognitive function in older adults (through IGF-1 mechanisms).

No equivalent RCT data exists for CJC-1295 and visceral fat specifically. CJC-1295 likely reduces visceral fat through the same downstream GH/IGF-1 mechanisms, but the evidence is extrapolated rather than directly demonstrated.

Body composition effects beyond fat

Both peptides raise IGF-1 and GH pulsatility, which produces overlapping benefits:

| Outcome | Tesamorelin Evidence | CJC-1295 Evidence | |---|---|---| | Visceral fat reduction | Strong RCT data | Indirect/extrapolated | | Lean mass preservation | Moderate | Moderate | | IGF-1 elevation | Documented in trials | Documented in studies | | Triglyceride reduction | Documented | Limited | | Cognitive function | Emerging data | Limited | | Sleep quality | Indirect | Anecdotal/indirect |

Cost and accessibility

Tesamorelin (Egrifta SV): The FDA-approved brand costs $3,000–$5,000/month at US pharmacy prices without insurance. With HIV-related coverage, costs may be offset. Through compounding pharmacies (where it's compounded off-label), tesamorelin runs approximately $200–$500/month depending on dose and source. Off-label compounded tesamorelin requires a prescription.

CJC-1295: Through research peptide vendors, $30–$80/month. Through compounding pharmacies with a prescription, $100–$200/month. No insurance coverage.

The cost difference between branded tesamorelin and research CJC-1295 is dramatic. Compounded tesamorelin narrows this gap but still costs more.

Who can access tesamorelin legally?

In the US, FDA-approved tesamorelin (Egrifta) is prescribed for HIV-associated lipodystrophy. Off-label prescribing is legal but less common given cost. Compounded tesamorelin is available through anti-aging and longevity clinics with a prescription—this is where most non-HIV patients access it.

CJC-1295 is available without prescription from research peptide vendors (though this is a regulatory gray area), or via prescription from anti-aging clinics.

Dosing protocols

Tesamorelin (off-label anti-aging/body composition):

• Dose: 1–2 mg subcutaneous injection daily
• Timing: Before bed
• Cycle: 3–6 months, with re-evaluation; some use continuously
• Monitoring: IGF-1 levels every 3 months

CJC-1295 no DAC (Mod GRF 1-29):

• Dose: 100–300 mcg subcutaneous injection
• Frequency: Daily, often paired with ipamorelin
• Timing: Before bed or fasted morning
• Cycle: 3–6 months

CJC-1295 with DAC:

• Dose: 1–2 mg subcutaneous injection
• Frequency: 1–2x per week
• Cycle: 8–12 weeks with breaks

When to choose tesamorelin

• Visceral fat is the primary target: The clinical evidence for VAT reduction is specifically for tesamorelin. If abdominal fat around organs is the primary concern, and you can access compounded tesamorelin at a reasonable cost, the evidence base is stronger.
• You need peer-reviewed clinical data to make decisions: Tesamorelin has the most robust human RCT data of any GHRH analog.
• You have a physician willing to prescribe it off-label: Best done with proper monitoring including IGF-1 tracking and metabolic labs.

When to choose CJC-1295

• Cost is a meaningful factor: Research CJC-1295 is dramatically cheaper.
• General GH optimization rather than specific VAT reduction: For sleep, recovery, body composition generally, CJC-1295 works through the same mechanism and is more practical.
• You want to combine with ipamorelin: CJC-1295 + ipamorelin is the most commonly prescribed combination in anti-aging medicine and a well-established protocol. See the CJC-1295 vs Sermorelin comparison for more context on GHRH analogs broadly.

The bottom line

Tesamorelin is the evidence-backed choice for visceral fat reduction specifically, with genuine Phase 3 RCT data showing meaningful VAT reduction. It's the FDA-approved standard for this application, though the drug price makes branded tesamorelin inaccessible for most. Compounded tesamorelin offers a middle ground. CJC-1295 is more practical, dramatically cheaper, more commonly used in anti-aging protocols, and works through the same receptor—but the specific visceral fat evidence is extrapolated from mechanism rather than directly demonstrated. For general GH optimization and anti-aging, CJC-1295 remains the pragmatic default.

---

Frequently Asked Questions

Q: Is tesamorelin more effective than CJC-1295 for fat loss? For visceral fat specifically, tesamorelin has direct Phase 3 evidence showing ~15–18% VAT reduction. CJC-1295 likely achieves similar effects via the same GH/IGF-1 mechanisms but lacks equivalent RCT evidence. Whether tesamorelin is molecularly superior (due to the full 44-AA sequence) or just better-studied is unclear—the practical difference at comparable effective doses may be minimal.

Q: Can tesamorelin be used for body composition in people without HIV? Yes, this is done off-label. Several studies have shown tesamorelin reduces visceral fat and improves metabolic markers in non-HIV adults with abdominal obesity. Compounding pharmacies can provide it with a prescription from a physician willing to prescribe off-label.

Q: Does tesamorelin raise blood sugar? Tesamorelin can modestly worsen glucose tolerance by raising GH/IGF-1, which affects insulin sensitivity. The FDA label notes this, and monitoring HbA1c and fasting glucose is recommended during use. This applies to all GH secretagogues to varying degrees but is particularly noted with tesamorelin at its approved doses.

Q: How does tesamorelin compare to the MK-677 approach for fat loss? MK-677 is an oral ghrelin mimetic that raises GH and IGF-1 through the ghrelin receptor—a completely different pathway from tesamorelin's GHRH receptor activation. MK-677 is associated with more significant water retention and potentially larger effects on appetite and blood sugar. Tesamorelin specifically targets the GHRH pathway with pulsatile GH release, which is more physiological. For visceral fat reduction specifically, tesamorelin has stronger direct evidence.

Q: Is there a reason to combine tesamorelin with ipamorelin? Yes—the same rationale that makes CJC-1295 + ipamorelin synergistic applies to tesamorelin + ipamorelin. A GHRH analog combined with a GHRP produces synergistic GH pulses. Some physicians prescribe tesamorelin + ipamorelin for patients seeking maximum GH stimulation. The combination is more expensive than CJC-1295 + ipamorelin but may produce greater GH release.

---

Monitor your IGF-1 levels and track peptide protocols with Optimize.